MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST002472/mwtabprimary200OKMass SpectrometryESIUlcerative Colitishttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST002472Matrix:Media_pool | Sample Type:QC_Titration | Tretment:-Matrix:Cell | Sample Type:Experiment | Tretment:Lactate+NitrateMatrix:Cell_pool | Sample Type:QC_Titration | Tretment:-Matrix:Cell | Sample Type:Experiment | Tretment:NitrateMatrix:Cell | Sample Type:Experiment | Tretment:LactateMatrix:Spent Media | Sample Type:Experiment | Tretment:NitrateMatrix:Unspent Media | Sample Type:Experiment | Tretment:LactateMatrix:Unspent Media | Sample Type:Experiment | Tretment:Lactate+NitrateMatrix:Spent Media | Sample Type:Experiment | Tretment:LactateMatrix:Unspent Media | Sample Type:Experiment | Tretment:NitrateMatrix:Spent Media | Sample Type:Experiment | Tretment:Lactate+NitrateBacterial CellsHILIC POSITIVE ION MODE. Reversed phase POSITIVE ION MODE.MetabolomicsWorkbenchMetabolomicsVeillonella ParvulaBroad Institute of MIT and HarvardTaurineTG 47:2TG 47:0TG 47:1PE P-36:2 or PE O-36:3Ser-ThrPhe-IleVal-Arg/Val-ArgTG 50:1TG 50:0EctoineTrp-ValPE 30:0Gly-ArgPhe-TrpAgmatineN-6-TrimethyllysineMG 18:0CAR DC3:0;2MeHis-PheLeu-TyrTG 58:2MethionineBiotinCitrullineTG 50:3TG 50:2Phe-MetN(6),N(6)-Dimethyl-lysineVal-HisL-HistidinolTG 46:1Phenylalanine-d8 [iSTD]TG 46:2CarnosineN-AcetylarginineTG 46:0Val-Ala3-MethoxytyramineArgininePE P-36:1 or PE O-36:2TriethanolamineAla-PheS-Methylcysteine S-oxideN-Acetylglutamic acidSerotoninPE P-34:2 or PE O-34:3His-ValDG 36:2Ser-ArgProline betaineDG 36:0DG 36:1Pantothenic acidValine-d8 [iSTD]TryptamineTG 49:2TG 49:3GuanosineTG 49:0Ala-IleTG 49:1CreatinesphingosineCytosinePhe-GlyMet-Lys/Lys-MetPhe-GluTyrosineCAR 18:0MG 16:1BiliverdinLys-IleN6-MethyladenosineLPC 16:1Ile-GlnTG 52:4TG 52:3TG 52:2TG 52:1TG 52:0Ala-AlaAla-HisHypoxanthineDG 35:1DG 35:2CE 16:0CE 16:1TG 48:3Leu-PheSerineC16 SphingosineTG 48:1TG 48:2Arg-ProAla-MetTG 48:0PutrescineThr-IlePhe-SerTG 51:0Phe-ThrAspartic acidThiaminePhe-TyrTriisopropanolamineLPC 17:0MG 14:0_bHomocitrullineGlu-IlePhe-LysTG 51:3TG 51:2Nicotinuric acidTG 51:1His-IleD-N-AcetylgalactosamineThr-TrpDG 34:2Tyr-LeuDG 34:3DG 34:0DG 34:1Pro-Ala/Ala-Pro5-MethylcytosineTrp-GlyTG 43:0N6-AcetyllysineHistidineLys-GlyAla-GluThr-ArgArg-MetLys-Gln3-MethylhistidineCaffeineTyramineThr-TyrThreonineVal-ProTG 54:6TG 54:5TG 54:4TG 54:3TG 54:2TG 54:1DeoxyadenosineUrocanic acidSer-IlePE 34:2Thr-ThrAcetaminophenLysineN-Acetylhistamine5-hydroxytryptophanN(6)-MethyllysineCE 18:2Thr-GlnCE 18:1HydroxyprolineNorharmaneTyr-ProTG 42:0Targininesn-Glycero-3-phosphocholineCreatinineMet-ValAlanineSer-Pro/Pro-SerC17 SphinganineN-AcetylhistidineIle-MetC16 SphinganineLys-SermyristoleateTyr-TyrC20 SphingosineAla-ArgC22 SphingosineVal-AsnCholineVal-AspN-AcetylleucineAsparagineDG 32:0DG 32:1LPE 18:1Thr-GluDG 32:2Nicotinic acidTG 45:0TG 45:1Pipecolic acidAsn-ArgVal-SerBetaineLys-ProDOPAPterinAla-LysN1-Methyl-2-pyridone-5-carboxamideAtenololVal-GlyCytidinePE 36:1CarnitineGly-ProN-MethylserotoninLys-TyrOleoyl-EADG 31:0LPE 15:0Thr-ProTyr-ValMethionine sulfoxideAla-Thr/Thr-AlaTG 44:1TG 44:2TG 44:0SphinganineVal-GlnheminSer-TrpHis-ProDG 38:2DeoxycytidineDG 30:03-hydroxynorvalineLPE 16:1other disease, host organism, Inflammatory Response, dTAF[[II]]230, TAF[[II]]250, d230, Microbial Competitive Behavior, Inflammations, disorders, TAF200, secondary metabolites, l(3)84Ab, dTAFII250, medical condition, BG:DS00004.13, TAFII-250, Microbial, TAF250/230, Behavior, EfW1, Cell, Competitive Behaviors, dTAF230, Microbial Competitive Behaviors, dmTAF[[II]]230, primary metabolites, TAFII250, Interaction, diseases, dmTAF1, Taf230, p230, Diseases, disease or disorder, TAF[[II]]250/230, condition, Competitive Behavior, TFIID, diseases and disorders, Microbial Interaction, Microbial Cooperative Behaviors, TAF250, Taf[[II]]250, Taf200, human disease, dTAF[[II]]250, TAF[[II]]230, inflammatory response, Cooperative Behaviors, TFIID TAF250, Micrococcus lactilyticus, cel, cell, Microbial Cooperative Behavior, metabolite, inflammation, Taf1p, TAF[II]250, CG17603, TAF[[II]], Micrococcus gazogenes alcalescens anaerobius, non-neoplastic, dTAF250, disease, Veillonella gazogenes, DmelCG17603, Cooperative Behavior, TAF1., Innate Inflammatory Response, Taf250, Staphylococcus parvulus, SR3-5, Innate Inflammatory Responses, Veillonella alcalescens, metabolites, Microbial Cooperative, Micrococcus gazogenes, disorder, Homo sapiens disease, associated, Behaviors, TAF, Innate, Microbial Competitive, Interactions, TAF230backward, reversed.falseLinking bacterial metabolites to disease-associated microbes to uncover mechanisms of host-microbial interactions in intestinal inflammation. Veillonella parvula cell and media profilingST00247229466